Metropolis Healthcare Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 10,038,822 (73%) | — | ₹88,342 Cr |
| NII (HNI) | — | 2,007,764 (15%) | — | ₹17,668 Cr |
| Retail | — | 1,338,509 (10%) | — | ₹1,178 Cr |
| Employee | — | 300,000 (2%) | — | ₹264 Cr |
| Σ Total | — | 13,685,095 (100%) | — | ₹1,204,288 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 17 | ₹14,960 |
| Retail (Max) | 13 | 221 | ₹194,480 |
| S-HNI (Min) | 14 | 238 | ₹209,440 |
| B-HNI (Min) | 67 | 1,139 | ₹1,002,320 |
Financial Statements Amount in Lakhs
| Metric | 31-Dec-18 | 31-Mar-18 | 31-Mar-17 |
|---|---|---|---|
| Revenue | 5,593 | 6,436 | 5,447 |
| Profit After Tax | 5,447 | 1,097 | 1,073 |
| Total Assets | 5,839 | 5,303 | 5,152 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- –
Company Overview
Incorporated in 1980, Mumbai based Metropolis Healthcare Limited is a chain of diagnostic companies. It has 106 clinical laboratories 1130 collection centres in seven countries. In India, it has laboratories across 18 states and 173 cities for monitoring of disease, early detection, and diagnostic screening.
The company also provides analytical and support services for the clinical research projects to some clinical research organizations. In the last financial year (2018), approximately 7.7 million patients visited the lab and around 16.0 million tests conducted in the clinics.
Metropolis offers 3,480 clinical laboratory tests and 524 profiles which combines a variety of tests for the specific disease. To provide better services, it has implemented a 'hub and spoke' model. Outside India, the company has a presence in Ghana, Zambia, Kenya, Sri Lanka and Mauritius for laboratory operations and in UAE, Nepal, Nigeria, and Oman for 3rd party services.
It has been recognized by Biotrains for "excellence in customer service and delivery" and FICCI for "service excellence (diagnostic center)" and LH Insights for "best in health and fitness" in 2018.
The competitive strengths of the company are:
1. Well positioned for expected industry growth
2. Widespread operational network
3. Comprehensive test menu
4. Focus on quality and customer service
5. Robust information technology structure